Rutschmann O T, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin L H
Division of Infectious Diseases and of Gastroenterology, University Hospital, Geneva, Switzerland.
J Infect Dis. 1998 Mar;177(3):783-5. doi: 10.1086/517808.
The impact of human immunodeficiency virus (HIV) protease inhibitors on hepatitis C (HCV) viremia was assessed in 19 patients infected with both HIV and HCV. HIV and HCV RNA levels were measured before and during treatment with protease inhibitors. Before treatment, mean levels of HCV RNA were 5.3 log for HCV RNA and 5.0 log for HIV RNA. CD4 lymphocyte counts were 63/mm3. After 6 weeks of treatment, a mean reduction of 2.1 log10 in HIV RNA (P < .001) and a mean (+/-SE) increase of 73 (+/-21) CD4 and 296 (+/-70) CD8 cells were observed (P < .05). In contrast, both HCV viremia (+0.4 log +/- 0.1) and alanine aminotransferase increased (P < .04). HCV RNA levels returned to baseline after 17 and 32 weeks of treatment. Thus, potent anti-HIV regimens with protease inhibitors may temporarily worsen HCV status despite improvement of HIV parameters.
在19例同时感染人类免疫缺陷病毒（HIV）和丙型肝炎病毒（HCV）的患者中评估了HIV蛋白酶抑制剂对HCV病毒血症的影响。在使用蛋白酶抑制剂治疗前及治疗期间测量HIV和HCV RNA水平。治疗前，HCV RNA的平均水平为5.3 log，HIV RNA的平均水平为5.0 log。CD4淋巴细胞计数为63/mm³。治疗6周后，观察到HIV RNA平均降低2.1 log10（P <.001），CD4细胞平均增加73（±21）、CD8细胞平均增加296（±70）（P <.05）。相比之下，HCV病毒血症（+0.4 log ± 0.1）和丙氨酸转氨酶均升高（P <.04）。治疗17周和32周后，HCV RNA水平恢复至基线。因此，尽管HIV参数有所改善，但使用蛋白酶抑制剂的强效抗HIV方案可能会使HCV病情暂时恶化。
